FDA patient, consumer reps often tied to pharma-funded groups
Patient and consumer representatives advising U.S. Food and Drug Administration (FDA) expert panels might actually be a Trojan horse for the pharmaceutical industry, a new study says.
A recent study raises concerns about the role of patient and consumer representatives advising the U.S. Food and Drug Administration (FDA). The research, published in Health Affairs Scholar, suggests that these representatives may have hidden ties to organizations funded by pharmaceutical companies. A 10-year analysis of nearly 240 FDA advisory committee meetings revealed that almost 40% of these gatherings included at least one patient or consumer representative with active industry connections.
Furthermore, in roughly 10% of drug review meetings, a representative's affiliated organization received funding from the drug's manufacturer. The ties were frequently not disclosed, potentially clouding the impartiality of the representatives. Lead author Genevieve Kanter, an associate professor at USC Schaeffer Center for Health Policy & Economics, stated that the relationships could indicate undue industry influence on advisory committees.
Previous studies show that a significant portion of patient advocacy organizations rely on donations from drug, device, and biotechnology companies. The study examined the prevalence of such ties in FDA advisory committees related to various drug categories, finding that committees for nervous system, GI, heart and kidney, and arthritis drugs had the highest proportion of representatives linked to pharma-funded advocacy groups.
Kanter emphasized the need for closer FDA scrutiny of these relationships, as they may not be considered conflicts of interest under current federal ethics laws but could still create the appearance of impartiality issues.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
